Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

ELDN Relative to the S&P 500

ELDN Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Eledon Pharmaceuticals, Inc. (NASD:ELDN) seasonal charts above shows that a Buy Date of August 16 and a Sell Date of November 5 has resulted in a geometric average return of 4.41% above the benchmark rate of the S&P 500 Total Return Index over the past 10 years. This seasonal timeframe has shown positive results compared to the benchmark in 4 of those periods. This is a poor rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 10 years by an average of 57.65% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company’s?compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

To download ELDN seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: ELDN